Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Patients with Severe Systemic-Onset Juvenile Idiopathic Arthritis Followed for 12 Months | Zendy

Е.I. Alexeeva | Zendy; Baranov Aa | Zendy; Р.В. Денисова | Zendy; С И Валиева | Zendy; Т.М. Бзарова | Zendy; К. Б. Исаева | Zendy; Т. В. Слепцова | Zendy; Е. В. Митенко | Zendy; N. I. Taybulatov | Zendy; Е. G. Chistyakova | Zendy; A. Fetisova | Zendy

Open Access

Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Patients with Severe Systemic-Onset Juvenile Idiopathic Arthritis Followed for 12 Months

Author(s) -

Е.I. Alexeeva,

Baranov Aa,

Р.В. Денисова,

С И Валиева,

Т.М. Бзарова,

К. Б. Исаева,

Т. В. Слепцова,

Е. В. Митенко,

N. I. Taybulatov,

Е. G. Chistyakova,

A. Fetisova

Publication year - 2013

Publication title -

isrn immunology

Language(s) - English

Resource type - Journals

eISSN - 2090-5653

pISSN - 2090-5645

DOI - 10.1155/2013/548312

Subject(s) - medicine , tocilizumab , leukopenia , neutropenia , refractory (planetary science) , arthritis , retrospective cohort study , juvenile , adverse effect , surgery , disease , chemotherapy , physics , astrobiology , biology , genetics

The results of the retrospective study evaluating efficacy and safety of tocilizumab treatment in 75 patients with severe systemic-onset juvenile idiopathic arthritis refractory to standard immunosuppressive therapy are presented in the paper. Inactive disease was documented in 64% of patients after 6 months of treatment and in 73% of patients after 12 months. Adverse events manifested as mild and moderate infections as well as laboratory abnormalities: leukopenia, neutropenia, and elevated aminotransferase levels.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research